<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">IJO</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21157086</article-id>
      <article-id pub-id-type="pmc">3032257</article-id>
      <article-id pub-id-type="publisher-id">IJO-59-73</article-id>
      <article-id pub-id-type="doi">10.4103/0301-4738.73707</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Visual acuity and electroretinography findings 3 &#xBD; years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shah</surname>
            <given-names>Parag K</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>Rodney J</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narendran</surname>
            <given-names>V</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kalpana</surname>
            <given-names>N</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
      </contrib-group>
      <aff id="AF0001">Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore &#x2013; 641 014, Tamilnadu, India</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to: Dr. Parag K. Shah, Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital, Avinashi Road, Coimbatore- 641 014, Tamil Nadu, India. E-mail: <email xlink:href="drshahpk2002@yahoo.com">drshahpk2002@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2011</year>
      </pub-date>
      <volume>59</volume>
      <issue>1</issue>
      <fpage>73</fpage>
      <lpage>74</lpage>
      <permissions>
        <copyright-statement>&#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>We reported the first case of intravitreal injection of bevacizumab (Avastin, Genentech, San Francisco, CA, USA) in aggressive posterior retinopathy of prematurity (APROP) in 2007.[<xref ref-type="bibr" rid="CIT1">1</xref>] Now we report visual acuity and electroretinography (ERG) findings of the same case, 3 &#xBD; years after the initial injection.</p>
    <p>A male born at 31 weeks of gestation and having a birth weight of 1170 g was diagnosed to have APROP. Immediate laser was done with almost 3,000 spots in each eye. One week after laser, both eyes developed anterior segment ischemia which was more severe in the left eye (LE). After taking an informed consent from the parents 0.03 ml bevacizumab (0.75 mg) was given intravitreally in LE. Right eye (RE) was managed conservatively. The features of anterior segment ischemia disappeared dramatically in LE after a single injection of bevacizumab, and at 10-month follow-up, fundus of both eyes showed regressed retinopathy of prematurity (ROP) with peripheral laser scars [<xref ref-type="fig" rid="F0001">Fig. 1</xref>]. Both eyes also developed lamellar cataracts which was more in LE.[<xref ref-type="bibr" rid="CIT1">1</xref>] The cataract in LE progressed further and retinoscopy increased to &#x2013;21 diopters (D) in both the axes. The RE retinoscopy was &#x2013;1.5 D. The axial length was 21.2 mm in LE and 18.7 mm in RE. Cataract surgery with primary posterior capsulorhexis, anterior vitrectomy, and posterior chamber intraocular lens implantation was done in LE. One month postsurgery his visual acuity was 20/180 in RE and 20/360 in LE on Teller&#x2019;s acuity chart. He was advised occlusion of RE for 6 h/day for 4 months. At 3 &#xBD; year follow-up, best corrected visual acuity was 20/30 in RE and only 20/500 in LE on Snellen acuity chart. There was no development delay seen in this child, and clinically the central nervous system, pulmonary, gastrointestinal, and renal systems were normal. Electro retinography (ERG) was done under general anesthesia. It showed subnormal and nearly extinguished B-wave in both eyes indicating extensive damage to rods and bipolar cells. The oscillatory potential response was present in both eyes, indicating near-normal vascularity. The cone response was noted as better than the rod response as indicated by the subnormal flicker ERG cone response. All the responses, although poor, were symmetrical in both eyes [<xref ref-type="fig" rid="F0002">Fig. 2</xref>].</p>
    <fig id="F0001" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Retcam pictures showing regressed retinopathy of prematurity (ROP) in both eyes with peripheral laser scars extending till zone 1. Bevacizumab was given in left eye</p>
      </caption>
      <graphic xlink:href="IJO-59-73-g001"/>
    </fig>
    <fig id="F0002" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Ganzfeld session summary of both eyes showing symmetrical subnormal electroretinography (ERG) waves</p>
      </caption>
      <graphic xlink:href="IJO-59-73-g002"/>
    </fig>
    <p>ERG changes are seen in ROP irrespective of laser treatment. Postlaser treatment, both rods[<xref ref-type="bibr" rid="CIT2">2</xref>] and cones get affected, although rods are affected more than cones.[<xref ref-type="bibr" rid="CIT3">3</xref>] More severe the ROP, more involved are the photoreceptors.[<xref ref-type="bibr" rid="CIT3">3</xref>] Since our case had a severe form of APROP and extensively lasered, the ERG was expected to be subnormal. Although bevacizumab was given in LE, the ERG waves were comparable to RE. However the visual acuity was poor, compared to the other eye. This poor visual acuity could be a side effect of bevacizumab or may be due to amblyopia.</p>
    <p>Our report suggests that intravitreal bevacizumab does not have an adverse effect on the ERG but could have on the final visual acuity. Thus, we urge caution in using it in premature babies till formal controlled studies with long-term follow-up are conducted to determine its potential safety in ROP.</p>
  </body>
  <back>
    <ref-list>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Narendran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tawansy</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Raghuram</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Narendran</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity</article-title>
          <source>Ind J Ophthalmol</source>
          <year>2007</year>
          <volume>55</volume>
          <fpage>75</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fulton</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Vanderveen</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <article-title>The rod photoreceptors in retinopathy of prematurity</article-title>
          <source>Arch Ophthalmol</source>
          <year>2001</year>
          <volume>119</volume>
          <fpage>499</fpage>
          <lpage>505</lpage>
          <pub-id pub-id-type="pmid">11296015</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fulton</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
            </name>
          </person-group>
          <article-title>The cone electroretinogram in retinopathy of prematurity</article-title>
          <source>Invest Ophthalmol Vis Sci</source>
          <year>2008</year>
          <volume>49</volume>
          <fpage>814</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">18235032</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
